Stoke Therapeutics (STOK) Property, Plant & Equipment (Net) Growth (3y) (2021 - 2026)
Powered by 
Analysis
Stoke Therapeutics (STOK) Property, Plant & Equipment (Net) Growth (3y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PP&E (Net) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.26 Bn | 131.41 Bn | 2.84 Bn | 14.05% |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn | 11.65% |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 411.50% |
| 4 | Moderna | 57.83 Bn | 52.69 Bn | 52.00 Mn | -3.34% |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.94 Bn | 34.84 Bn | 1.53 Bn | 16.78% |
| 7 | Alnylam Pharmaceuticals | 35.19 Bn | 31.88 Bn | 992.69 Mn | 1.66% |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn | 19.96% |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.66 Bn | - | -9.30% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -9.30% |
| Mar 31, 2026 | -20.63% |
| Dec 31, 2025 | -22.18% |
| Sep 30, 2025 | -24.49% |
| Jun 30, 2025 | -17.10% |
| Mar 31, 2025 | -10.49% |
| Dec 31, 2024 | -1.89% |
| Sep 30, 2024 | 13.76% |
| Jun 30, 2024 | 18.26% |
| Mar 31, 2024 | 24.87% |
| Dec 31, 2023 | 29.60% |
| Sep 30, 2023 | 29.05% |
| Jun 30, 2023 | 31.86% |
| Mar 31, 2023 | 31.85% |
| Dec 31, 2022 | 38.51% |
| Sep 30, 2022 | 54.49% |
| Jun 30, 2022 | 50.48% |
| Dec 31, 2021 | 51.43% |